Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
June 2018 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the June BNF eNewsletter.
Three new drug monographs have been added to the BNF in the last month, benralizumab, emicizumab and midostaurin and two new drug monographs to the BNFC, emtricitabine with tenofovir disoproxil, and ipilimumab.

This issue includes dose changes for bosutinib, candesartan cilexetil, nivolumab, and raltegravir, as well as updated guidance on the management of chronic asthma, vaccines: Hepatitis A vaccine, and vaccines for travel: Hepatitis A. We have included MHRA advice about obeticholic acid and the risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring. You will also find NICE technology appraisals for brodalumab for treating moderate to severe plaque psoriasis, cabozantinib for treating medullary thyroid cancer, and regorafenib for previously treated advanced hepatocellular carcinoma.
Kind regards,
BNF Team
I In this issue
BNF 75 case studies More >  
MedicinesComplete is now live More >  
Significant changes More >  
News More >  
How to purchase BNF More >  
Drug safety update More >  
Feedback More >  
I Sign up for the new BNF 75 case studies
Based on the BNF 75, this new series includes 3 clinical case studies that explore common medical conditions, how to identify potential hazards and provide effective treatment.

If you're an online BNF user, access the additional content on MedicinesComplete by clicking the interactive links in the case study, which link through to the relevant content pages.

Sign up here to download your copy
BNF 75 case studies Volume 1
I New MedicinesComplete is now live!
We hope you're now enjoying your use of the new site. Please remember, access to the legacy site is no longer available, so please ensure you continue to get familiar with the new platform.

To help you navigate your way around we've created a user guide to help you get to grips with all the new features and benefits. There is a helpful FAQ's section on the site to help you with any general queries and our support team is available to help should you have any questions about the new platform.

If you have any general or specific feedback on your MedicinesComplete experience, log in and then click on the blue Feedback tab on the right hand side of the page.

Remember to forward this email to your colleagues so they are also aware of the latest updates to MedicinesComplete.

Best wishes,
The MedicinesComplete team
I Significant changes
This month's changes to the clinical content of these publications are described in three parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNFC update should be read by all users of the BNF for Children
BNF 72 - BNFC 2016-2017
BNF BNF for Children Update
Emicizumab: new drug monograph
For further information, see emicizumab.
Quinine: clarification of parenteral dose of quinine for the treatment of malaria [dose reduction necessary if parenteral treatment is required for more than 48 hours]
For further information, see quinine.
Asthma, chronic: updated guidance on management
For further information, see asthma, chronic.
Immunoglobulins: updated guidance for varicella-zoster immunoglobulin)
For further information, see immunoglobulins.
Vaccines: updated guidance for Hepatitis A vaccine
For further information, see vaccines.
Vaccines for travel: updated guidance on Hepatitis A
For further information, see vaccines for travel.
BNF for Children Update
Ipilimumab: new drug monograph
For further information, see ipilimumab.
Emtricitabine with tenofovir disoproxil: new drug monograph
For further information, see Emtricitabine with tenofovir disoproxil.
Dose changes
Co-codamol [doses for children aged 12 to 15 years]
For further information, see co-codamol.
Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide [age-range extension]
For further information, see Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide.
Ganciclovir [update to indications and doses]
For further information, see ganciclovir.
Raltegravir [dose for oral suspension; update to directions for administration]
For further information, see raltegravir.
Other changes
To review other changes in BNF for Children, click on changes.
BNF Update
Benralizumab: new drug monograph
For further information, see benralizumab.
Midostaurin: new drug monograph
For further information, see midostaurin.
Obeticholic acid (Ocaliva®): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring [MHRA advice]
For further information, see obeticholic acid.
Dose changes
Bosutinib [dose in renal impairment]
For further information, see bosutinib.
Candesartan cilexetil [clarification of maximum daily dose in heart failure]
For further information, see candesartan cilexetil.
Nivolumab [doses for monotherapy]
For further information, see nivolumab.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Brodalumab for treating moderate to severe plaque psoriasis
Cabozantinib for treating medullary thyroid cancer
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Obinutuzumab for untreated advanced follicular lymphoma
Regorafenib for previously treated advanced hepatocellular carcinoma
Tivozanib for treating advanced renal cell carcinoma
Other changes
To review other changes in BNF, click on changes.
I News
Reminder - help from CPPE with BNF 75
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 75. It comprises 10 practical case studies that help you keep up to date with recent changes in the BNF, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2018 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2018 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2018 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.